vs
优尼威（CLMB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是优尼威的1.2倍（$219.9M vs $182.4M），优尼威净利率更高（1.8% vs -1.0%，领先2.8%），优尼威同比增速更快（32.1% vs 2.0%），过去两年优尼威的营收复合增速更高（40.7% vs 8.0%）
优尼威解决方案是一家全球化学品与原料分销商，同时可为客户提供各类增值服务，在行业内拥有广泛的全球布局与专业服务能力。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CLMB vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$182.4M
营收增速更快
CLMB
高出30.1%
2.0%
净利率更高
CLMB
高出2.8%
-1.0%
两年增速更快
CLMB
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.4M | $219.9M |
| 净利润 | $3.3M | $-2.2M |
| 毛利率 | 14.5% | 71.1% |
| 营业利润率 | 2.1% | 0.2% |
| 净利率 | 1.8% | -1.0% |
| 营收同比 | 32.1% | 2.0% |
| 净利润同比 | -9.5% | 92.4% |
| 每股收益（稀释后） | $0.18 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMBOFIX
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $219.9M | ||
| Q3 25 | $161.3M | $205.6M | ||
| Q2 25 | $159.3M | $203.1M | ||
| Q1 25 | $138.0M | $193.6M | ||
| Q4 24 | $161.8M | $215.7M | ||
| Q3 24 | $119.3M | $196.6M | ||
| Q2 24 | $92.1M | $198.6M |
净利润CLMBOFIX
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $-2.2M | ||
| Q3 25 | $4.7M | $-22.8M | ||
| Q2 25 | $6.0M | $-14.1M | ||
| Q1 25 | $3.7M | $-53.1M | ||
| Q4 24 | $7.0M | $-29.1M | ||
| Q3 24 | $5.5M | $-27.4M | ||
| Q2 24 | $3.4M | $-33.4M |
毛利率CLMBOFIX
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 71.1% | ||
| Q3 25 | 15.9% | 72.2% | ||
| Q2 25 | 16.5% | 68.7% | ||
| Q1 25 | 16.9% | 62.8% | ||
| Q4 24 | 19.3% | 69.0% | ||
| Q3 24 | 20.3% | 68.7% | ||
| Q2 24 | 20.2% | 67.8% |
营业利润率CLMBOFIX
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 0.2% | ||
| Q3 25 | 4.3% | -8.3% | ||
| Q2 25 | 5.0% | -7.9% | ||
| Q1 25 | 3.5% | -25.2% | ||
| Q4 24 | 7.2% | -5.3% | ||
| Q3 24 | 7.1% | -9.6% | ||
| Q2 24 | 4.6% | -12.5% |
净利率CLMBOFIX
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | -1.0% | ||
| Q3 25 | 2.9% | -11.1% | ||
| Q2 25 | 3.7% | -6.9% | ||
| Q1 25 | 2.7% | -27.4% | ||
| Q4 24 | 4.3% | -13.5% | ||
| Q3 24 | 4.6% | -13.9% | ||
| Q2 24 | 3.7% | -16.8% |
每股收益（稀释后）CLMBOFIX
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $-0.05 | ||
| Q3 25 | $1.02 | $-0.57 | ||
| Q2 25 | $1.30 | $-0.36 | ||
| Q1 25 | $0.81 | $-1.35 | ||
| Q4 24 | $1.52 | $-0.76 | ||
| Q3 24 | $1.19 | $-0.71 | ||
| Q2 24 | $0.75 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.8M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $118.4M | $450.0M |
| 总资产 | $458.8M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLMBOFIX
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $82.0M | ||
| Q3 25 | $49.8M | $62.9M | ||
| Q2 25 | $28.6M | $65.6M | ||
| Q1 25 | $32.5M | $58.0M | ||
| Q4 24 | $29.8M | $83.2M | ||
| Q3 24 | $22.1M | $30.1M | ||
| Q2 24 | $48.4M | $26.4M |
总债务CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益CLMBOFIX
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $450.0M | ||
| Q3 25 | $109.3M | $442.5M | ||
| Q2 25 | $105.2M | $458.3M | ||
| Q1 25 | $95.6M | $458.3M | ||
| Q4 24 | $90.6M | $503.1M | ||
| Q3 24 | $87.7M | $525.9M | ||
| Q2 24 | $79.8M | $546.0M |
总资产CLMBOFIX
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $850.6M | ||
| Q3 25 | $376.1M | $832.6M | ||
| Q2 25 | $420.7M | $837.2M | ||
| Q1 25 | $370.1M | $823.1M | ||
| Q4 24 | $469.2M | $893.3M | ||
| Q3 24 | $371.9M | $867.9M | ||
| Q2 24 | $302.8M | $882.0M |
负债/权益比CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $27.7M | ||
| Q3 25 | $22.2M | $12.4M | ||
| Q2 25 | $-2.2M | $11.6M | ||
| Q1 25 | $8.5M | $-18.4M | ||
| Q4 24 | $16.0M | $23.7M | ||
| Q3 24 | $-3.6M | $11.7M | ||
| Q2 24 | $7.3M | $9.0M |
自由现金流CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率CLMBOFIX
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLMB
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
